Cost-effectiveness analysis of pharmacogenomics (PGx)-based warfarin, apixaban, and rivaroxaban versus standard warfarin for the management of atrial fibrillation in Ontario, Canada
Hafeez A, Cipriano LE, Kim RB, Zaric GS, Schwarz UI, Sarma S. Pharmacoeconomics. 2023; Aug 19 [Epub ahead of print].